A team from Germany and the USA prospectively analyzed the interventional and clinical aspects of computed tomography (CT)-guided direct intratumoral administration of a novel cisplatin/epinephrine gel for treatment of malignant liver tumors
A total of 8 patients with 17 colorectal liver metastases and 9 patients with 13 hepatocellular carcinoma nodules were included in the trial.
They were treated with CT-guided local injections of cisplatin/epinephrine gel (mean of 5.1 and 3.1 injections for metastases and hepatocellular carcinoma groups, respectively).
This application provided a higher local, and lower systemic, drug concentration.
Volumes of tumor and necrosis prior and after treatment were measured by computer generated volumetric analysis.
Contrast enhanced studies verified pre-therapeutic viable tumor volumes with a value of 77.4 ml in the metastases and 29.2 ml in the hepatocellular carcinoma nodules.
|Local therapy control rates:|
Hepatocellular carcinoma: 71%
| British Journal of Cancer |
Intratumoral drug application resulted in a significant increase of necrosis and a decrease in viable tumor volume to be 68.3 ml in metastases and 14.5 ml in hepatocellular carcinoma.
Local therapy control rates at 6-month follow-up were found to be 38% and 71% for the metastases and hepatocellular carcinoma groups, respectively.
Author T. J. Vogl, of the University of Frankfurt, Germany, concluded on behalf of colleagues, "Direct intratumoral injection of cisplatin/epinepthrine gel is a feasible and well-tolerated method.
"It resulted in the development of a statistically significant increase in necrosis in malignant liver tumors.
"A higher local therapy control rate can be reported for hepatocellular carcinoma compared to colorectal metastases."